Drive-Pain

Drive-PainDrive-PainDrive-Pain

Drive-Pain

Drive-PainDrive-PainDrive-Pain
  • HOME
  • Hypothesis
  • RESULTS
    • Phase 1
    • Phase 2
    • Phase 3
    • Dissemination
  • Contact
  • More
    • HOME
    • Hypothesis
    • RESULTS
      • Phase 1
      • Phase 2
      • Phase 3
      • Dissemination
    • Contact

  • HOME
  • Hypothesis
  • RESULTS
    • Phase 1
    • Phase 2
    • Phase 3
    • Dissemination
  • Contact

DEVELOPMENT OF A COMPUTATIONAL ALGORITHM FOR DRUG REPURPOSING - IDENTIFICATION OF ENZYME INHIBITORS

IDENTIFICATION OF MOLECULES FOR CHRONIC PAIN THERAPY

FAAH INHIBITORS

FAAH INHIBITORS

FAAH INHIBITORS

Using QSAR analysis and molecular docking studies we identified five molecules as potential FAAH inhibitors: raloxifene, revefenacin, montelukast, ebastine and repaglinide. Following the in vitro analysis, we confirmed the inhibitory action on FAAH of the selected compounds, with the most intense inhibitory action being observed for montelukast.

MAGL INHibITORS

FAAH INHIBITORS

FAAH INHIBITORS

Using QSAR analysis and molecular docking studies, they identified as potential MAGL inhibitors: doxepin, olopatadine, cetirizine, hydroxyzine, levetiracetam. Following the in vitro analysis, the inhibitory action on MAGL of the selected compounds was confirmed, the most intense inhibitory action being observed for levetiracetam, doxepin and cetirizine.

Copyright © 2022 Drive-Pain - All Rights Reserved.

Powered by AZ

  • Privacy Policy